key: cord-0715490-0nybx1fb
authors: Bürgi, Justus J.; Rösslein, Matthias; Hornung, Henry; Jentsch, Jana; Boller, Viveka L.; Dollenmaier, Günter; Wick, Peter; Peier, Karen; Nohynek, Brigitte; Fischer, Aldo; Stolz, Raphael; Cettuzzi, Michele; Reut, Michael; Boy, Regine Garcia; Nolte, Oliver; Korte, Wolfgang
title: Divergent humoral responses in mild to moderate SARS-CoV-2 infection over time – indication of persistence of the virus?: Indication of persistence of SARS-CoV-2?
date: 2021-11-06
journal: J Infect
DOI: 10.1016/j.jinf.2021.11.001
sha: 4a55caa443895aca163aad38a2fa1ec4983fda1f
doc_id: 715490
cord_uid: 0nybx1fb

nan

-Detailed longitudinal serological description (14 month) of mild to moderate COVID-19 -All participants followed for 14 month showed antibodies at the final study visit -Anti-spike IgG is initially gender dependent and switches to age dependence -The anti-spike IgA levels of the majority of participants are gradually increasing -The results are indicating a subtle anti-spike IgA stimulus Keywords: SARS-CoV-2; Serology; Antibodies; COVID-19; IgA

Serum antibodies are an important pillar of the immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. With preliminary data, we have shown that SARS-CoV-2 IgG and IgA antibody response is both, gender dependent and characterized by a declining antibody concentration early on (1) . We can now show that antibodies, especially against spike protein (S), remain detectable for more than one year in most persons with PCR confirmed mild to moderate COVID-19 despite the fact that a relevant decline can be observed. We here present the extended longitudinal profile of IgG and IgA against S and of IgG against nucleocapsid protein (N) for more than one year (initiated during the first infection wave in Switzerland in March 2020). The study includes outpatients with a history of positive SARS-CoV-2 PCR, i.e. a mild to moderate disease course. The cohort comprises 278 individuals (12.0 -91.2 years, median = 51.2, IQR = 25.8; 59.5% females), of which 53 (24.8 -91.2 years, median = 55.8, IQR = 13.9; 41% females) were followed for 14 months (Supplementary table 1 ). The study is registered in the Swiss COVID-19 database (https://swissethics.ch/covid-19/approved-projects; K2) and was approved by the regional ethics committee (ID2020-00941). PCR analysis of stool and swab based nasopharyngeal samples were performed together with blood draws every week in the first month and then after another four weeks in the second month. All SARS-CoV-2 enzyme-linked immunosorbend assays (ELISA; anti-S IgG and IgA, Euroimmun, Lübeck, Germany; anti-N IgG, Epitope Diagnostics, San Diego, USA) were run on an automated DSX ELISA processor (Dynex Technologies) according to the recommendations of the manufacturers. We defined an OD ratio of 11 for anti-S IgG and an OD ratio of 9 for anti-S IgA as the upper threshold of the dynamic range, since the assays saturate above this points (2) . Statistical definitions, analysis and visualization were based on or performed with software R using the implemented statistical tests and the packages "tidyverse" and "ggplot2" (3). During the initial 4 months after positive PCR result, 94.2% of participants showed quantifiable evidence of seroconversion, while 5.8% did not ( Fig. 1 A-C). Upon their first visit (median 6 weeks after positive PCR; 95% CI 0.43 weeks) 11.9% (33 / 278), 21.6% (60 / 278) and 24.5% (68 / 278) had not developed measurable anti-S IgG, anti-S IgA or anti-N IgG, respectively. Furthermore, 66.9% of participants displayed quantifiable antibody concentrations for all three entities evaluated. Remarkably, in the long-term sub cohort, all participants presented at least one quantifiable antibody entity at all time points until their last visit, while 49% showed quantifiable antibody concentrations in all three entities. Note that study participants with no detectable antibodies against SARS-CoV-2 initially (5.8%) did not participate in the long-term sub cohort. The earlier observed statistically significant gender-associated difference in the antibody concentrations persist for the first 3 months; thereafter, gender-associated differences are no longer observed (1) . In addition to the initial gender-associated differences, there is a significant (p < 2.1e-08) age dependent difference in antibody concentrations starting from weeks 22-26 ( Fig. 1 D) . Individuals younger than 54 years of age tend to show lower antibody concentrations than their older counterparts; this was also observed in other studies (4). While antibody concentrations may have complex kinetics (5), we categorized the anti-S antibody longitudinal courses based on the slope of the robust regression line (Fig. 2) . We identified two statistically distinctive patterns of antibody dynamics for anti-S IgG and IgA: declining antibody concentrations (decrease of anti-S IgG levels, average slope: -0.045 (±0.037) OD ratio/week, n = 47; decrease of anti-S IgA levels, average slope: -0.032 (±0.052) OD ratio/week, n = 19) and increasing antibody concentrations (increase of anti-S IgG levels, average slope: +0.029 (±0.020) OD ratio/week, n = 6; increase of anti-S IgA levels, average slope: +0.053 (±0.066) OD ratio/week, n = 34). The majority (89%) of the long-term sub cohort showed declining anti-S IgG antibody concentrations. Most interestingly, a small subgroup (11%) showed increasing antibody concentrations over time (Fig. 2 B ). An even higher proportion of increasing antibody concentrations was observed analyzing the individual courses of anti-S IgA antibodies (36% declining and 64% increasing antibody concentrations). As there are substantially more individual anti-S IgA courses showing increasing antibody concentrations, this might indicate an underling mechanism of IgA stimulation. The detection of SARS CoV-2 material in some stool samples early during the observation period might be hinting at such a stimulatory exposure (Supplementary table 2) . Considering all results of our observation, one might therefore conclude that IgA antibodies might provide a more persistent and more stable defense to SARS-CoV-2 than IgG (6, 7) . According to the current understanding, one has to expect a steep but continuous decrease in antibody concentration (in the absence of the antigen) after an initial increase (5). Our current data, however, describe a secondary increase in anti-spike IgG in a few and in IgA in much more patients. If this increase was due to re-infection, a much steeper increase (i.e. a booster) could be expected to be observed, at least temporarily (8) . In addition, nasopharyngeal swabs and stool samples for PCR testing were taken at every visit, but none of them were found positive results in any of the individuals within this group; obviously, this observation does not allow to rule out a potential re-infection or re-exposure during the observation period with certainty. However, it seems at least to rule out persistence of a high viral load in the nasopharynx and the gut within this group. However, even non-detectable persistence of virus particles might have provided sufficient antigens to induce a response, preventing waning of antibodies. Such findings have been described either for coronavirus particles found in the small bowel of convalescent study participants or by durable antigen presentation on follicular dendritic cells (9, 10) . The observed IgA antibody incremental increase indicate a chronic infection state (5) and may help to understand how our immune system copes with this virus. (D) Gender and age specific dynamic changes in anti-S IgG antibody levels over time. 1 = female individuals with age higher than 54 years; 2 = female individuals with age lower than 54 years; 3 = male individuals with age higher than 54 years; 4 = male individuals with age lower than 54 years.

Individual longitudinal anti-spike IgG and anti-spike IgA courses were analyzed utilizing robust regression (period week 17 to 57) using an MM estimator, which is an M-estimation with Turkey's biweight initialized by a specific S-estimator. The corresponding slopes were categorized according to the following properties of their individual course: Declining antibody concentrations were defined by a negative slope value (slope < 0 OD ratio/week); increasing antibody concentrations were defined by a positive slope value (slope > 0 OD ratio/week). Blue line represents an illustrative line indicating the average present slope calculated by the robust regression of data from week 17 to week 57; dotted magenta line indicate OD ratio at 1.1 (positive cut-off); dotted black line indicate optical density (OD) ratio of 0.8 (values below are considered negative); grey shaded region in-between OD ratio 0.8-1.1 contains borderline results. Each point represents a single measurement. (A) anti-spike IgG (n = 47, 89%) and IgA (n = 19, 36%) antibody levels with declining tendency. (B) anti-spike IgG (n = 6, 11%) and IgA (n = 34, 64%) antibody levels with increasing tendency.

This work was supported by the Center for Laboratory Medicine, the Swiss Federal Laboratories for Materials Science and Technology St. Gallen (Empa) and the Canton of St. Gallen.

SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on

Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection

Welcome to the Tidyverse

SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity

Mechanisms that determine plasma cell lifespan and the duration of humoral immunity

Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies

Evolution of antibody immunity to SARS-CoV-2

Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques

We thank all the participants who agreed to participate in this study as well as the physicians, nurses and members from Polipraxis in St. Gall, Praxis Seidenbaum in Trübbach and the hematology outpatient department of the center for laboratory medicine in St. Gall, Switzerland, who participated in this study.

The authors declare that they have no competing interests.